Scientific Reports (May 2022)

TDP-43 regulates cholesterol biosynthesis by inhibiting sterol regulatory element-binding protein 2

  • Naohiro Egawa,
  • Yuishin Izumi,
  • Hidefumi Suzuki,
  • Itaru Tsuge,
  • Koji Fujita,
  • Hitoshi Shimano,
  • Keiichi Izumikawa,
  • Nobuhiro Takahashi,
  • Kayoko Tsukita,
  • Takako Enami,
  • Masahiro Nakamura,
  • Akira Watanabe,
  • Motoko Naitoh,
  • Shigehiko Suzuki,
  • Tsuneyoshi Seki,
  • Kazuhiro Kobayashi,
  • Tatsushi Toda,
  • Ryuji Kaji,
  • Ryosuke Takahashi,
  • Haruhisa Inoue

DOI
https://doi.org/10.1038/s41598-022-12133-4
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Dyslipidemia is considered an essential component of the pathological process of amyotrophic lateral sclerosis (ALS), a fatal motor neuron disease. Although TAR DNA Binding Protein 43 kDa (TDP-43) links both familial and sporadic forms of ALS and cytoplasmic aggregates are a hallmark of most cases of ALS, the molecular mechanism and the in vivo relation of ALS dyslipidemia with TDP-43 have been unclear. To analyze the dyslipidemia-related gene expression by TDP-43, we performed expression microarray and RNA deep sequencing (RNA-Seq) using cell lines expressing high levels of TDP-43 and identified 434 significantly altered genes including sterol regulatory element-binding protein 2 (SREBP2), a master regulator of cholesterol homeostasis and its downstream genes. Elevated TDP-43 impaired SREBP2 transcriptional activity, leading to inhibition of cholesterol biosynthesis. The amount of cholesterol was significantly decreased in the spinal cords of TDP-43-overexpressed ALS model mice and in the cerebrospinal fluids of ALS patients. These results suggested that TDP-43 could play an essential role in cholesterol biosynthesis in relation to ALS dyslipidemia.